<DOC>
	<DOCNO>NCT00668356</DOCNO>
	<brief_summary>The purpose study show administration 400/mg/m2/day didanosine ( ddI ) meal bioequivalent administration 240/mg/m2/day didanosine fasting , HIV infect child treat ARV combination include ddI</brief_summary>
	<brief_title>Bioequivalence Study Didanosine Children Treated HIV</brief_title>
	<detailed_description>The didanosine one reverse transcriptase inhibitor . This drug efficient viral replication HIV . Licensing child obtain June , 1992 . The main problem didanosine poor bioavailability : although gastro-resistant capsule develop , bioavailability remain dependent alimentation . Taking meal 1-2 hour administration ddI lead reduction 50 % bioavailability well child adult . It therefore recommend take ddI fasting period . This regimen case decrease therapeutic observance . A pharmacokinetic study ddI conduct meal 240 mg/m2/day fasting period compare 400 mg/m2/day meal . 26 patient , age 6 year old , include randomised 2 group . The first group take standard dose ddI 28 day fast period ( phase A ) , high dose meal 28 day ( phase B ) . The second group take first phase B secondly phase A . Patients sequentially evaluate first second period treatment pharmacokinetics biological analysis .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Children treat didanosine capsule 3 month viral load &lt; 50 copies/ml write informed consent Normal renal function Lack observance Any treatment interact ddI No write informed consent Weight &gt; 60 kg</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>HIV disease child</keyword>
	<keyword>HIV</keyword>
	<keyword>child</keyword>
	<keyword>didanosine</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>treatment experience</keyword>
</DOC>